Scholarlink

<p>Radiotherapy (RT) is a clinical mainstay of cancer treatment that triggers tumor-specific immune responses. However, the effectiveness is usually hampered due to the hypoxic tumor microenvironment (TME) and the ambivalent impact of RT on the immune landscape of tumors. Herein, we develop an injectable hydrogel encapsulating interleukin-12 (IL-12)/anti-CTLA-4 (aCTLA-4) co-engineered red blood cells (RBC), which is in situ self-assembled within the TME to increase oxygen supply and instigate sequential aCTLA-4/IL-12 release, thus achieving Ba/O<sub>2</sub> self-compensated radiosensitization and activating multistage immune responses. Once in the acidic TME, the in situ injected BaO<sub>2</sub> undergoes hydrolysis to generate H<sub>2</sub>O<sub>2</sub> and Ba<sup>2+</sup>, followed by the rapid reaction of Ba<sup>2+</sup> with sodium alginate to afford a biocompatible hydrogel. Meanwhile, catalase presented on RBC converts H<sub>2</sub>O<sub>2</sub> into O<sub>2</sub>, thereby alleviating hypoxia-induced radioresistance and inducing O<sub>2</sub>-mediated pore formation on RBC membrane for rapid release of aCTLA-4 to relieve tumor immunosuppression. Subsequently, IL-12 anchored on RBC is dilatorily released and interacts with T/NK cells within the TME to induce IFN-γ-dependent antitumor immunity. Taken together, the in situ self-assembled cell reservoir hydrogel offers a futuristic avenue to realize multistage radioimmunotherapy for effective tumor regression by programmable immunoregulation with significant clinical value.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Yue Chen,
  • Qinyi Chen,
  • Yuanyuan Ma,
  • Cheng Zhang,
  • Jie Xu,
  • Kejing Li,
  • Yajie Sun,
  • Xinge Su,
  • Mingguang Wei,
  • Rui Bao,
  • Tong Ding,
  • Longguang Tang,
  • Wenying Yu,
  • Shenghong Ju,
  • Wenpei Fan

摘要

Radiotherapy (RT) is a clinical mainstay of cancer treatment that triggers tumor-specific immune responses. However, the effectiveness is usually hampered due to the hypoxic tumor microenvironment (TME) and the ambivalent impact of RT on the immune landscape of tumors. Herein, we develop an injectable hydrogel encapsulating interleukin-12 (IL-12)/anti-CTLA-4 (aCTLA-4) co-engineered red blood cells (RBC), which is in situ self-assembled within the TME to increase oxygen supply and instigate sequential aCTLA-4/IL-12 release, thus achieving Ba/O2 self-compensated radiosensitization and activating multistage immune responses. Once in the acidic TME, the in situ injected BaO2 undergoes hydrolysis to generate H2O2 and Ba2+, followed by the rapid reaction of Ba2+ with sodium alginate to afford a biocompatible hydrogel. Meanwhile, catalase presented on RBC converts H2O2 into O2, thereby alleviating hypoxia-induced radioresistance and inducing O2-mediated pore formation on RBC membrane for rapid release of aCTLA-4 to relieve tumor immunosuppression. Subsequently, IL-12 anchored on RBC is dilatorily released and interacts with T/NK cells within the TME to induce IFN-γ-dependent antitumor immunity. Taken together, the in situ self-assembled cell reservoir hydrogel offers a futuristic avenue to realize multistage radioimmunotherapy for effective tumor regression by programmable immunoregulation with significant clinical value.